Audit Review Table
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, SubID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2018; Date & Timestamp - 6/13/2019 4:06:43 PM The Auditor lock has been applied to this submission.				
Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment
Effectiveness of Care: Prevention and	Bellett Officied	ruic	Addit Designation	Genment
Adult BMI Assessment (aba)		77.86%	R	Reportable
, ,		11.0070		repertable
Weight Assessment and Counseling for Nutrition and				
Physical Activity for Children/Adolescents				
(wcc)				
BMI Percentile		46.23%	R	Reportable
Counseling for Nutrition		51.82%	R	Reportable
Counseling for Physical Activity		42.09%	R	Reportable
Childhood Immunization Status (cis)				
DTaP		75.67%	R	Reportable
IPV		88.56%	R	Reportable
MMR		89.78%	R	Reportable
HiB		84.43%	R	Reportable
Hepatitis B		89.05%	R	Reportable
VZV		89.54%	R	Reportable
Pneumococcal Conjugate		76.16%	R	Reportable
Hepatitis A		88.08%	R	Reportable
Rotavirus		71.05%	R	Reportable
Influenza		54.26%	R	Reportable
Combination #2		72.99%	R	Reportable
Combination #3		69.59%	R	Reportable
Combination #4		68.61%	R	Reportable
Combination #5		60.34%	R	Reportable
Combination #6		47.20%	R	Reportable
Combination #7		59.61%	R	Reportable
Combination #8		46.72%	R	Reportable
Combination #9		43.31%	R	Reportable
Combination #10		42.82%	R	Reportable
Immunizations for Adolescents (ima)				·
Meningococcal		71.05%	R	Reportable
Tdap		82.24%	R	Reportable
HPV		35.28%	R	Reportable
Combination #1		69.34%	R	Reportable
Combination #2		32.60%	R	Reportable
Lead Screening in Children (Isc)		42.39%	R	Reportable
Breast Cancer Screening (bcs)		42.49%	R	Reportable
Cervical Cancer Screening (ccs)		51.82%	R	Reportable
Chlamydia Screening in Women (chl)		0.1.0270		. topoliusio
16-20 Years		45.20%	R	Reportable
21-24 Years		53.31%	R	Reportable
Total		49.38%	R	Reportable
Effectiveness of Care: Respiratory		10.0070	1,	roportable
Appropriate Testing for Children with Pharyngitis (cwp)	Y	75.18%	R	Reportable
Use of Spirometry Testing in the Assessment and				
Diagnosis		27.85%	R	Reportable
of COPD (spr)				
Pharmacotherapy Management of COPD Exacerbation	Y			
(pce)	Y			
Systemic Corticosteroid		41.74%	R	Reportable
Bronchodilator		51.83%	R	Reportable
Modication Management for Beenla With Asthma (www.)	Y			
Medication Management for People With Asthma (mma)	ſ			
5-11 Years: Medication Compliance 50%		54.25%	R	Reportable
5-11 Years: Medication Compliance 75%		26.14%	R	Reportable
12-18 Years: Medication Compliance 50%		49.17%	R	Reportable
12-18 Years: Medication Compliance 75%		26.52%	R	Reportable
19-50 Years: Medication Compliance 50%		63.57%	R	Reportable
19-50 Years: Medication Compliance 75%		37.82%	R	Reportable
		68.28%	R	Reportable
51-64 Years: Medication Compliance 50%				
51-64 Years: Medication Compliance 50% 51-64 Years: Medication Compliance 75%		52.69%	R	Reportable
		52.69% 59.42%	R R	Reportable Reportable

Asthma Medication Ratio (amr)	Y			
5-11 Years	'	74.84%	R	Reportable
12-18 Years		60.63%	R	Reportable
19-50 Years		42.69%	R	Reportable
51-64 Years		49.82%	R	Reportable
Total		54.05%	R	Reportable
Effectiveness of Care: Cardiovascular Controlling High Blood Pressure (cbp)		48.66%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart				'
Attack (pbh)	Y	58.54%	R	Reportable
Statin Therapy for Patients With Cardiovascular	Υ			
Disease (spc)		CO 440/	D	Donostokia
Received Statin Therapy: 21-75 Years (Male) Statin Adherence 80%: 21-75 Years (Male)		69.41% 52.59%	R R	Reportable Reportable
Received Statin Therapy: 40-75 Years (Female)		46.96%	R	Reportable
Statin Adherence 80%: 40-75 Years (Female)		50.93%	R	Reportable
Received Statin Therapy: Total		61.07%	R	Reportable
Statin Adherence 80%: Total		52.12%	R	Reportable
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)		02.070/	D	Donostokia
Hemoglobin A1c (HbA1c) Testing HbA1c Poor Control (>9.0%)		82.97% 50.61%	R R	Reportable Reportable
HbA1c Control (<8.0%)		39.90%	R	Reportable
HbA1c Control (<7.0%)		30.0070	NR	Not Reported
Eye Exam (Retinal) Performed		53.77%	R	Reportable
Medical Attention for Nephropathy		88.56%	R	Reportable
Blood Pressure Control (<140/90 mm Hg)		55.72%	R	Reportable
Statin Therapy for Patients With Diabetes (spd)	Y		_	
Received Statin Therapy Statin Adherence 80%		43.92% 49.49%	R R	Reportable
Effectiveness of Care: Musculoskeletal		49.49%	R	Reportable
Disease-Modifying Anti-Rheumatic Drug Therapy in		05.740/		5
Rheumatoid Arthritis (art)	Y	65.71%	R	Reportable
Effectiveness of Care: Behavioral				
Antidepressant Medication Management (amm)	<u>Y</u>	10.100/		
Effective Acute Phase Treatment		49.12% 32.79%	R R	Reportable
Effective Continuation Phase Treatment Follow-Up Care for Children Prescribed ADHD		32.1970	K	Reportable
Medication (add)	Υ			
Initiation Phase		49.32%	R	Reportable
Continuation and Maintenance (C&M) Phase		58.95%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Υ			
6-17 years - 30-Day Follow-Up		50.00%	R	Reportable
6-17 years - 7-Day Follow-Up		30.48%	R	Reportable
18-64 years - 30-Day Follow-Up		33.23%	R	Reportable
18-64 years - 7-Day Follow-Up		19.59%	R	Reportable
65+ years - 30-Day Follow-Up		33.33%	NA	Small Denominator
65+ years - 7-Day Follow-Up Total - 30-Day Follow-Up		27.78%	NA D	Small Denominator
Total - 7-Day Follow-Up		35.80% 21.33%	R R	Reportable Reportable
· · ·		21.5570	IX	Reportable
Follow-Up After Emergency Department Visit for Mental Illness (fum)	Υ			
6-17 years - 30-Day Follow-Up		68.11%	R	Reportable
6-17 years - 7-Day Follow-Up		52.76%	R	Reportable
18-64 years - 30-Day Follow-Up		49.48%	R	Reportable
18-64 years - 7-Day Follow-Up		36.02%	R	Reportable
65+ years - 30-Day Follow-Up		18.18%	NA NA	Small Denominator
65+ years - 7-Day Follow-Up Total - 30-Day Follow-Up		9.09% 52.80%	NA R	Small Denominator
Total - 3U-Day Follow-Up Total - 7-Day Follow-Up		39.02%	R R	Reportable Reportable
Follow-Up After Emergency Department Visit for		00.0270		Торонало
Alcohol and Other Drug Abuse or Dependence (fua)	Y			
00.5 5 11 11 10 17 17		4.00%	R	Reportable
30-Day Follow-Up: 13-17 Years				
7-Day Follow-Up: 13-17 Years		4.00%	R	Reportable
7-Day Follow-Up: 13-17 Years 30-Day Follow-Up: 18+ Years		4.00% 17.14%	R	Reportable
7-Day Follow-Up: 13-17 Years		4.00%		·

	T		•	
Diabetes Screening for People With Schizophrenia or				
Bipolar Disorder Who Are Using Antipsychotic	Y	79.07%	R	Reportable
Medication (ssd)				
Diabetes Monitoring for People With Diabetes and		47.070/		5
Schizophrenia (smd)		47.67%	R	Reportable
Cardiovascular Monitoring for People With				
Cardiovascular		50.00%	NA	Small Denominator
Disease and Schizophrenia (smc)				
Adherence to Antipsychotic Medications for Individuals	.,	54.400/	_	5
With Schizophrenia (saa)	Y	51.16%	R	Reportable
Metabolic Monitoring for Children and Adolescents on	Υ			
Antipsychotics (apm)				
1-5 Years		11.11%	NA	Small Denominator
6-11 Years		29.41%	R	Reportable
12-17 Years		37.50%	R	Reportable
Total		34.16%	R	Reportable
Effectiveness of Care: Medication				
Annual Monitoring for Patients on Persistent	Υ			
Medications (mpm)		00.040/		Daniel II
ACE Inhibitors or ARBs		83.04%	R	Reportable
Diuretics Total		84.60% 83.62%	R R	Reportable
Effectiveness of Care:		63.02%	K	Reportable
Non-Recommended Cervical Cancer Screening in				
Adolescent		0.99%	R	Reportable
Females (ncs)		0.0070	• • • • • • • • • • • • • • • • • • • •	r toportubio
Appropriate Treatment for Children With URI (uri)	Υ	89.97%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute				
Bronchitis (aab)	Y	34.79%	R	Reportable
` '				
Use of Imaging Studies for Low Back Pain (lbp)		68.29%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children	Y			
Adolescents (apc)	Y			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		0.89%	R	Reportable
12-17 Years		2.12%	R	Reportable
Total		1.63%	R	Reportable
Use of Opioids at High Dosage (uod)	Y	3.52%	R	Reportable
Use of Opioids From Multiple Providers (uop)	Υ			
Multiple Prescribers		20.08%	R	Reportable
Multiple Pharmacies		7.67%	R	Reportable
Multiple Prescribers and Multiple Pharmacies		3.64%	R	Reportable
Risk of Continued Opioid Use (cou)	Y			
18-64 years - >=15 Days covered		9.39%	R	Reportable
18-64 years - >=31 Days covered		4.12%	R	Reportable
65+ years - >=15 Days covered		31.82%	NA NA	Small Denominator
65+ years - >=31 Days covered		22.73%	NA D	Small Denominator
Total ->=15 Days covered		9.44%	R	Reportable
Total - >=31 Days covered Access/Availability of Care		4.15%	R	Reportable
Adults' Access to Preventive/Ambulatory Health				
Services (aap)				
20-44 Years		71.71%	R	Reportable
45-64 Years		79.93%	R	Reportable
65+ Years		87.19%	R	Reportable
Total		75.44%	R	Reportable
Children and Adolescents' Access to Primary Care				
Practitioners (cap)			_	-
12-24 Months		95.39%	R	Reportable
25 Months - 6 Years		86.87%	R	Reportable
7-11 Years		88.20%	R	Reportable
12-19 Years	Y	86.82%	R	Reportable
Annual Dental Visit (adv) 2-3 Years	Y Y	62.38%	R	Reportable
2-3 Years 4-6 Years		73.07%	R R	Reportable
7-10 Years		76.15%	R	Reportable
11-14 Years		70.95%	R	Reportable
TI-14 Teals		10.5070	1	reportable

15-18 Years		60.25%	R	Reportable
19-20 Years		41.98%	R	Reportable
Total		67.90%	R	Reportable
Initiation and Engagement of AOD Abuse or				·
Dependence	Υ			
Treatment (iet)				
Alcohol abuse or dependence: Initiation of AOD Treatment:		53.70%	R	Reportable
13-17 Years				·
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years		9.26%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment:				
13-17 Years		50.00%	NA	Small Denominator
Opioid abuse or dependence: Engagement of AOD				
Treatment: 13-17 Years		0.00%	NA	Small Denominator
Other drug abuse or dependence: Initiation of AOD		E4 420/	Б	Reportable
Treatment: 13-17 Years		51.43%	R	Reportable
Other drug abuse or dependence: Engagement of AOD		16.43%	R	Reportable
Treatment: 13-17 Years				·
Total: Initiation of AOD Treatment: 13-17 Years		47.46%	R	Reportable
Total: Engagement of AOD Treatment: 13-17 Years		15.25%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment:		39.33%	R	Reportable
18+ Years Alcohol abuse or dependence: Engagement of AOD				<u> </u>
		12.80%	R	Reportable
Treatment: 18+ Years Opioid abuse or dependence: Initiation of AOD Treatment:				
18+ Years		53.20%	R	Reportable
Opioid abuse or dependence: Engagement of AOD			_	
Treatment: 18+ Years		28.01%	R	Reportable
Other drug abuse or dependence: Initiation of AOD		20.770/	Б	Depositable
Treatment: 18+ Years		39.77%	R	Reportable
Other drug abuse or dependence: Engagement of AOD		10.83%	R	Reportable
Treatment: 18+ Years				·
Total: Initiation of AOD Treatment: 18+ Years		41.21%	R	Reportable
Total: Engagement of AOD Treatment: 18+ Years		15.32%	R	Reportable
Alcohol abuse or dependence: Initiation of AOD Treatment:		39.59%	R	Reportable
Total				
Alcohol abuse or dependence: Engagement of AOD Treatment: Total		12.74%	R	Reportable
Opioid abuse or dependence: Initiation of AOD Treatment:				
Total		53.18%	R	Reportable
Opioid abuse or dependence: Engagement of AOD		a= aaa/	_	
Treatment: Total		27.86%	R	Reportable
Other drug abuse or dependence: Initiation of AOD		40.38%	R	Reportable
Treatment: Total		40.3676	N.	Reportable
Other drug abuse or dependence: Engagement of AOD		11.12%	R	Reportable
Treatment: Total				·
Total: Initiation of AOD Treatment: Total		41.38%	R	Reportable
Total: Engagement of AOD Treatment: Total		15.32%	R	Reportable
Prenatal and Postpartum Care (ppc)			_	
Timeliness of Prenatal Care		80.78%	R	Reportable
Postpartum Care		63.50%	R	Reportable
Use of First-Line Psychosocial Care for Children and	Υ			
Adolescents on Antipsychotics (app) 1-5 Years		83.33%	NA	Small Denominator
6-11 Years		50.94%	R	Reportable
12-17 Years		53.13%	R	Reportable
Total		53.55%	R	Reportable
Utilization		33.3370	, n	T Treboltable
Well-Child Visits in the First 15 Months of Life (w15)				
O Visits		2.97%	R	Reportable
1 Visit		2.01%	R	Reportable
2 Visits		3.63%	R	Reportable
3 Visits		4.83%	R	Reportable
4 Visits		9.45%	R	Reportable
5 Visits		14.98%	R	Reportable
6+ Visits		62.14%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth				·
Years of Life (w34)		60.09%	R	Reportable
Adolescent Well-Care Visits (awc)		35.50%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			R	Reportable

Ambulatory Care: Dual Eligibles (ambb)		ND	Not Deported
Ambulatory Care: Dual Engibles (ambb) Ambulatory Care: Disabled (ambc)		NR NR	Not Reported Not Reported
Ambulatory Care: Other (ambd)		NR NR	Not Reported Not Reported
Inpatient UtilizationGeneral Hospital/Acute Care:		NIX	Not Reported
Total (ipua)		R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Dual Eligibles (ipub)		NR	Not Reported
Inpatient UtilizationGeneral Hospital/Acute Care: Disabled (ipuc)		NR	Not Reported
Inpatient UtilizationGeneral Hospital/Acute Care: Other (ipud)		NR	Not Reported
Identification of Alcohol and Other Drug Services: Total (iada)	Υ	R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	Y	NR	Not Reported
Identification of Alcohol and Other Drug Services: Disabled (iadc)	Y	NR	Not Reported
Identification of Alcohol and Other Drug Services: Other (iadd)	Υ	NR	Not Reported
Mental Health Utilization: Total (mpta)	Υ	R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	Y	NR	Not Reported
Mental Health Utilization: Disabled (mptc)	Y	NR	Not Reported
Mental Health Utilization: Other (mptd)	Υ	NR	Not Reported
Antibiotic Utilization: Total (abxa)	Y	R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Y	NR	Not Reported
Antibiotic Utilization: Disabled (abxc)	Y	NR	Not Reported
Antibiotic Utilization: Other (abxd)	Υ	NR	Not Reported
Risk Adjusted Utilization			
Plan All-Cause Readmissions (pcr)		R	Reportable
Health Plan Descriptive		l III	Un acceditated
Board Certification (bcr)		UN	Unaudited
Enrollment by Product Line: Total (enpa)		R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)		NR NR	Not Reported
Enrollment by Product Line: Disabled (enpc) Enrollment by Product Line: Other (enpd)		NR NR	Not Reported Not Reported
Enrollment by Product Line. Other (empa)		R	Reportable
Language Diversity of Membership (Idm)		NR NR	Not Reported
Race/Ethnicity Diversity of Membership (rdm)		NR NR	Not Reported
Total Membership (tlm)		R	Reportable
Measures Collected using Electronic			
Depression Screening and Follow-Up for Adolescents			
and Adults (dsf)			
Depression Screening: Total Total		NR	Not Reported
Follow-up on Positive Screen: Total Total		NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms			
for Adolescents and Adults (dms)		=	
Utilization of PHQ-9 - Time period 1: Total Total		NR NB	Not Reported
Utilization of PHQ-9 - Time period 2: Total Total		NR NB	Not Reported
Utilization of PHQ-9 - Time period 3: Total Total		NR NB	Not Reported
Utilization of PHQ-9 - Total: Total Total Depression and Remission or Response for		NR	Not Reported
Adolescents and Adults (drr)			
Follow-up PHQ-9: Total Total		NR	Not Reported
Depression Remission: Total Total		NR	Not Reported
Depression Response: Total Total		NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)			
Alcohol Use Screening: Total Total		NR	Not Reported
Counseling or Other Follow-up Postive Screen: Total Total		NR	Not Reported
Adult Immunization Status (ais)			
Influenza: Total		NR	Not Reported
Td or Tdap: Total		NR	Not Reported
Zoster: Total		NR	Not Reported
Composite: Total		NR	Not Reported
Prenatal Immunization Status (prs) Influenza: Total		ND	Not Paparted
Td or Tdap: Total		NR NB	Not Reported
Ta or Taap: Total		NR	Not Reported

Combination: Total NR Not Reported